Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Alvelestat · MPH-966, AZD-9668

Small molecule · Inhibitor of neutrophil elastase (ELANE) · developed by Mereo BioPharma

Phase 2 Most advanced trial (none active)
MREO Developer
4 Registered trials

What is Alvelestat?

Alvelestat is an orally bioavailable, selective and reversible inhibitor of human neutrophil elastase, a serine protease released by neutrophils during inflammation. It is being studied in lung diseases such as chronic obstructive pulmonary disease, emphysema and alpha-1 antitrypsin deficiency.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MPH-966, AZD-9668
Drug type
Small molecule
Targets
neutrophil elastase (ELANE)
Mechanism
Inhibitor of neutrophil elastase (ELANE)
Pathways
neutrophil-mediated inflammation, lung inflammation and injury
Therapy area
Infectious disease, Oncology, Respiratory
Developer
Mereo BioPharma (MREO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
6Y5629322X

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03986086 Phase 1/2 Hematologic Malignancy Withdrawn MREO
NCT04539795 Phase 1/2 Covid19 Completed MREO
NCT03679598 Phase 2 Alpha-1 Antitrypsin Deficiency (AATD) Completed MREO
NCT03636347 Phase 2 Alpha 1-Antitrypsin Deficiency Completed MREO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alpha 1-Antitrypsin DeficiencyAlpha-1 Antitrypsin Deficiency (AATD)COPDCovid19EmphysemaEmphysema or COPDHematologic Malignancy

More from Mereo BioPharma

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the MREO page.

Follow MREO, the company behind Alvelestat

See MREO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MREO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.